

ACRUX ENTERS COMMERCIAL MANUFACTURING ALLIANCE WITH ORION CORPORATION

Melbourne, 14 August 2008: Acrux (ASX: ACR) announced today that it has entered into a commercial manufacturing alliance with European pharmaceutical company Orion Corporation (OMX: ORNAV, ORNBV). Orion has a market capitalisation of approximately EUR 1.8 billion and reported turnover of EUR 683 million and operating profit of EUR 192 million in 2007.

Orion will manufacture finished products for Acrux on a commercial scale, at its FDA-approved facility in Finland. Orion Corporation develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets.

Under the agreement, Acrux has appointed Orion as the exclusive commercial manufacturer of Testosterone MD-Lotion[®], which will enable Acrux to supply product to licensees in all territories, targeting a global market of \$0.9 billion growing at 20% per annum. Acrux recently announced the commencement of the Phase 3 trial and expects to file marketing applications in the USA and Europe in the 4th quarter of 2009, with Orion as the authorised manufacturer.

In addition, Orion will have the capability to manufacture transdermal spray (MDTS[®]) finished products exclusively for Acrux as a range of products utilising its unique drug delivery technology are commercialised globally.

The alliance involves an investment by both companies in additional infrastructure at the Orion facility. The investment by Acrux forms part of the existing budget for the Testosterone MD-Lotion[®] Phase 3 programme.

“This agreement secures finished product supply for both our Testosterone MD-Lotion[®] and our MDTS[®] transdermal spray products such as Ellavie[™] and in so doing it represents a crucial element in our overall commercialisation strategy”, said Acrux CEO Richard Treagus.

14.08.08

Acrux Limited
103-113 Stanley Street
West Melbourne
VIC 3003 Australia

Tel: +61 3 8379 0100
Fax: +61 3 8379 0101
E-mail: info@acrux.com.au
www.acrux.com.au



“We are very pleased to be strongly aligned with a company having both the capabilities and scale of Orion”.

Contact:

Richard Treagus, Acrux CEO and Managing Director
+ 61 417 520 509

About Acrux - www.acrux.com.au

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.
- Acrux has one product, EvaMist™ (brand name Ellavie™ outside the USA) to treat menopause symptoms, marketed by its licensee in the USA and has the following products in clinical development:
 - Testosterone MD-Lotion® to treat male testosterone deficiency
 - Testosterone MDTS® to treat decreased libido in women
 - Nestorone® MDTS® contraceptive sprays for women
 - An undisclosed companion animal health product
 - Fentanyl MDTS® to treat chronic pain
 - Nicotine MDTS® for smoking cessation
- Acrux has licensed worldwide rights to its technology for selected contraceptives and for an undisclosed proprietary drug to ORGANON, USA rights for Estradiol MDTS® to KV Pharmaceutical and for Testosterone MDTS® to VIVUS, and AUS/NZ distribution rights for Estradiol MDTS® to Aspen Pharmacare and for Testosterone MDTS® and Fentanyl MDTS® to CSL Limited. Acrux has also licensed its technology to Eli Lilly and Company for veterinary healthcare products.

About Orion Corporation

www.orion.fi/english

Orion is the leading Finnish pharmaceutical company with a history of over 90 years. In addition to a broad portfolio of pharmaceuticals for both human and veterinary use, the company also manufactures active pharmaceutical ingredients and point-of-care diagnostic tests based on in-house development. Orion's strong and active engagement in R&D has generated seven innovative medicinal treatments to global markets, the brightest stars being Stalevo® and Comtess®/Comtan® (entacapone) for Parkinson's Disease. Orion's strategy emphasises European-wide own marketing operations while global market access is arranged via partnerships. The Orion Group's net sales in 2007 were EUR 683.6 million and in the end of 2007 there were about 3,170 employees working for the Group. Orion's shares (ORNAV, ORNBV) are listed on the Nasdaq OMX Nordic Exchange Helsinki.

Acrux Limited
103-113 Stanley Street
West Melbourne
VIC 3003 Australia

Tel: +61 3 8379 0100
Fax: +61 3 8379 0101
E-mail: info@acrux.com.au
www.acrux.com.au

